Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Fig. 2

BMD Loss was repressed by ZOL treatment in HIV patients receiving tenofovir treatment. a Model-based mean longitudinal changes in BMD at the lumbar spine in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. b Model-based mean BMD percentage change at the lumbar spine from baseline in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. c Model-based mean longitudinal changes in lumbar spine t scores in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. d Model-based mean longitudinal changes in lumbar spine z scores in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment

Back to article page